Meta-analyses after confirmed these findings, highlighting the efficacy of SGLT2 inhibitors in reducing kidney disease progression and CV events across various patient populations, irrespective of diabetes status or underlying kidney disease [28]. Here, SLC5A2 is linked to kidney disorder.